Search

Your search keyword '"Bolzoni, M"' showing total 3 results
Start Over Author "Bolzoni, M" Journal haematologica
3 results on '"Bolzoni, M"'

1. The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1 inhibition in myeloma cells

Author

Storti, P., primary, Toscani, D., additional, Airoldi, I., additional, Marchica, V., additional, Maiga, S., additional, Bolzoni, M., additional, Fiorini, E., additional, Campanini, N., additional, Martella, E., additional, Mancini, C., additional, Guasco, D., additional, Ferri, V., additional, Donofrio, G., additional, Aversa, F., additional, Amiot, M., additional, and Giuliani, N., additional

Published
2015
Full Text
View/download PDF

2. IL21R expressing CD14 + CD16 + monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Author

Bolzoni M, Ronchetti D, Storti P, Donofrio G, Marchica V, Costa F, Agnelli L, Toscani D, Vescovini R, Todoerti K, Bonomini S, Sammarelli G, Vecchi A, Guasco D, Accardi F, Palma BD, Gamberi B, Ferrari C, Neri A, Aversa F, and Giuliani N

Subjects
Biomarkers, Bone Marrow Cells metabolism, Bone Marrow Cells pathology, Cluster Analysis, Cytokines metabolism, Female, Gene Expression Profiling, Humans, Immunophenotyping, Lipopolysaccharide Receptors metabolism, Male, Monoclonal Gammopathy of Undetermined Significance genetics, Monoclonal Gammopathy of Undetermined Significance metabolism, Monoclonal Gammopathy of Undetermined Significance pathology, Multiple Myeloma metabolism, Phenotype, RNA, Messenger genetics, RNA, Messenger metabolism, Receptors, IgG metabolism, Receptors, Interleukin-21 metabolism, Gene Expression, Monocytes metabolism, Multiple Myeloma genetics, Multiple Myeloma pathology, Osteoclasts metabolism, Receptors, Interleukin-21 genetics
Abstract

Bone marrow monocytes are primarily committed to osteoclast formation. It is, however, unknown whether potential primary alterations are specifically present in bone marrow monocytes from patients with multiple myeloma, smoldering myeloma or monoclonal gammopathy of undetermined significance. We analyzed the immunophenotypic and transcriptional profiles of bone marrow CD14 + monocytes in a cohort of patients with different types of monoclonal gammopathies to identify alterations involved in myeloma-enhanced osteoclastogenesis. The number of bone marrow CD14 + CD16 + cells was higher in patients with active myeloma than in those with smoldering myeloma or monoclonal gammopathy of undetermined significance. Interestingly, sorted bone marrow CD14 + CD16 + cells from myeloma patients were more pro-osteoclastogenic than CD14 + CD16-cells in cultures ex vivo Moreover, transcriptional analysis demonstrated that bone marrow CD14 + cells from patients with multiple myeloma (but neither monoclonal gammopathy of undetermined significance nor smoldering myeloma) significantly upregulated genes involved in osteoclast formation, including IL21R IL21R mRNA over-expression by bone marrow CD14 + cells was independent of the presence of interleukin-21. Consistently, interleukin-21 production by T cells as well as levels of interleukin-21 in the bone marrow were not significantly different among monoclonal gammopathies. Thereafter, we showed that IL21R over-expression in CD14 + cells increased osteoclast formation. Consistently, interleukin-21 receptor signaling inhibition by Janex 1 suppressed osteoclast differentiation from bone marrow CD14 + cells of myeloma patients. Our results indicate that bone marrow monocytes from multiple myeloma patients show distinct features compared to those from patients with indolent monoclonal gammopathies, supporting the role of IL21R over-expression by bone marrow CD14 + cells in enhanced osteoclast formation., (Copyright© Ferrata Storti Foundation.)

Published
2017
Full Text
View/download PDF

3. The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Author

Storti P, Toscani D, Airoldi I, Marchica V, Maiga S, Bolzoni M, Fiorini E, Campanini N, Martella E, Mancini C, Guasco D, Ferri V, Donofrio G, Aversa F, Amiot M, and Giuliani N

Subjects
Animals, Caspase 3 genetics, Caspase 3 immunology, Cyclin-Dependent Kinase Inhibitor p27 genetics, Cyclin-Dependent Kinase Inhibitor p27 immunology, Disease Models, Animal, Humans, Hypoxia-Inducible Factor 1, alpha Subunit antagonists & inhibitors, Hypoxia-Inducible Factor 1, alpha Subunit immunology, Ikaros Transcription Factor genetics, Ikaros Transcription Factor immunology, Interferon Regulatory Factors genetics, Interferon Regulatory Factors immunology, Lenalidomide, Mice, Mice, Inbred NOD, Mice, SCID, Mitogen-Activated Protein Kinase 1 genetics, Mitogen-Activated Protein Kinase 1 immunology, Mitogen-Activated Protein Kinase 3 genetics, Mitogen-Activated Protein Kinase 3 immunology, Multiple Myeloma genetics, Multiple Myeloma immunology, Multiple Myeloma pathology, Plasma Cells immunology, Plasma Cells pathology, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, S-Phase Kinase-Associated Proteins genetics, S-Phase Kinase-Associated Proteins immunology, Signal Transduction, Thalidomide pharmacology, Trans-Activators genetics, Trans-Activators immunology, Gene Expression Regulation, Neoplastic, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Immunologic Factors pharmacology, Multiple Myeloma therapy, Plasma Cells drug effects, Thalidomide analogs & derivatives
Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results